VEGF receptor kinase inhibitors (Novartis/Bayer Schering)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameVEGF receptor kinase inhibitors (Novartis/Bayer Schering)
Drug Alias NameVEGF receptor kinase inhibitors (Novartis/Schering)ABP-309ZK260255AAL-993
ClassificationSmall molecules
Mechanisms of ActionStem cell growth factor receptor inhibitorsPlatelet-derived growth factor receptor inhibitorsAngiogenesis inhibitors +[5] 
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptorVascular endothelial growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis AgBayer Schering Pharma AG
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A